FDA & Government News

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

Share

  • 1

    Deucravacitinib (Sotyktu) is now FDA approved for active psoriatic arthritis.

  • 2

    It is the first TYK2 inhibitor for this indication.

  • 3

    Phase 3 trials showed significant improvements versus placebo.

  • 4

    ACR20 response was 54% in two trials.

  • 5

    Common adverse effects include respiratory infections and herpes simplex.

  • 6

    The drug targets TYK2 pathways involved in inflammation.

  • 7

    Patients had documented plaque psoriasis.

  • 8

    Treatment improves disease activity and response rates.

Original Source(s)

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

  • by Kathryn Wighton

  • March 9, 2026

  • 3 min

Related Content

Upadacitinib and Pain in RA, PsA

Mediation analysis suggests direct and indirect effects on pain reduction in rheumatoid and psoriatic arthritis.

PsA Clusters Identified for Tailored Treatment: Longitudinal Study

Discovery of Novel Susceptibility Gene May Shed Light on Etiology of Psoriatic Arthritis Mutilans

Researchers may have uncovered genetic mechanisms underlying psoriatic arthritis mutilans.